P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Paolo F. Caimi(University Hospitals Seidman Cancer Center), Carmelo Carlo‐Stella(Humanitas University), Mehdi Hamadani(Medical College of Wisconsin), John Radford(Manchester Academic Health Science Centre), Brian Hess(Washington University in St. Louis), Anastasios Stathis(Princess Margaret Cancer Centre), Weiyun Z. Ai(City College of San Francisco), Kirit M. Ardeshna(UCL Biomedical Research Centre), Brad S. Kahl(UW Health University Hospital), Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Ying Wang, Yajuan Qin, Luqiang Wang(Tianjin Medical University Eye Hospital), Cindy Xu(Rapt Therapeutics (United States)), Melhem Solh(Johns Hopkins Hospital)
Cited by 3
Related Papers
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791